Jiangsu Wuzhong Pharmaceutical Group Corporation announced a equity round of funding for gross proceeds of CNY 340 million with existing investor JiangSu WuZhong Pharmaceutical Development Co., Ltd. on January 5, 2022. As a part of the round, the registered capital of the company will increase from CNY 400 million to CNY 740 million. Post the capital increase, the investor will retain its 100% stake in the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.08 CNY | -2.80% | +1.51% | +22.63% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+22.63% | 981M | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- 600200 Stock
- News JiangSu WuZhong Pharmaceutical Development Co., Ltd.
- Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.